Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 2/20 | 0.58 |
| ▸ | POLB | P06746 | 1/20 | 0.57 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | TP53 | P04637 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
| ▸ | ATM | Q13315 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6139487 | 0.93 | MGLL (0.62) | MGLLPOLBENPP2NPC1ALDH1A1 | |
| SCHEMBL3937278 | 0.93 | MGLL (0.62) | MGLLPOLBENPP2NPC1ALDH1A1 | |
| SCHEMBL655257 | 0.90 | MGLL (0.66) | MGLLPOLBENPP2NPC1ALDH1A1 | |
| SCHEMBL9459601 | 0.90 | MGLL (0.66) | MGLLPOLBENPP2NPC1ALDH1A1 | |
| SCHEMBL4871235 | 0.88 | KDM4E (0.56) | MGLLPOLBENPP2NPC1ALDH1A1 | |
| SCHEMBL2529957 | 0.85 | KDM4E (0.59) | MGLLPOLBNPC1ALDH1A1RAB9A | |
| SCHEMBL6400257 | 0.84 | MGLL (0.72) | MGLLPOLBENPP2NPC1ALDH1A1 | |
| SCHEMBL3197311 | 0.84 | L3MBTL1 (0.54) | MGLLPOLBNPC1TP53MAPT | |
| SCHEMBL28423480 | 0.83 | MGLL (0.58) | MGLLPOLBENPP2NPC1ALDH1A1 | |
| SCHEMBL27613056 | 0.83 | MGLL (0.58) | MGLLPOLBENPP2NPC1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080132477-A1 | Macrocyclic Compounds Useful as Bace Inhibitors | NOVARTIS AG (CH) | 2008-06-05 | — | — | US | disclosed |
| EP-1851208-A1 | MACROCYCLIC COMPOUNDS USEFUL AS BACE INHIBITORS | Novartis AG (CH) | 2007-11-07 | — | — | EP | disclosed |
| WO-2006074950-A1 | MACROCYCLIC COMPOUNDS USEFUL AS BACE INHIBITORS | NOVARTIS AG (CH) | 2006-07-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080132477-A1 | Macrocyclic Compounds Useful as Bace Inhibitors | BACE1, BACE2, APP | MGLL 2688/4885POLB 356/4885ENPP2 599/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.